We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Evogene Ltd | NASDAQ:EVGN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.07 | 2.49% | 2.88 | 2.76 | 3.07 | 2.955 | 2.80 | 2.83 | 10,583 | 01:00:00 |
Date: August 22, 2024 |
|
EVOGENE LTD.
(Registrant) By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer |
EXHIBIT NO.
|
DESCRIPTION
|
- |
On June 25, Casterra announced receiving a $440K purchase order to supply castor seeds to a new African country in 2024. This order from an existing customer expands Casterra's operations and strengthens its position in the bio-fuel
market.
|
- |
On July 31, Casterra announced the successful completion of its castor seed growing and harvesting season in Brazil, with shipments planned for the third quarter of 2024. Additionally, the castor harvest season in Africa has begun as
scheduled.
|
- |
Castor seeds produced in 2024 in both Brazilian and African territories are expected to enable Casterra to meet all its existing orders, amounting to approximately $8.4M, with completion anticipated by the end of this year.
|
- |
On July 2, Lavie Bio announced the commercial expansion of its bio-inoculant Yalos™ to winter wheat following successful trials, with sales starting across the US for the 2024-2025 season, effectively doubling its market potential.
|
- |
On July 22, 2024, Lavie Bio announced a milestone in its collaboration with ICL in developing bio-stimulant solutions for row crops facing extreme weather conditions by leveraging AI to identify over a dozen novel microbes within 12
months.
|
- |
Lavie Bio's pipeline is advancing according to plan, with field trials initiated in Q2 in most of the company’s programs, following successful optimization processes. Results are expected during Q4.
|
- |
On May 23, positive safety and tolerability data for BMC128 was published. 72% of the patients treated have exhibited clinical benefits. 55% of patients showed sustained clinical benefit, with notable durations of effect (more than 24
months).
|
- |
These clinical results were presented at the prestigious 2024 ASCO annual conference in June.
|
- |
We look forward to continuing to evaluate BMC128’s beneficial activity in subsequent phases of clinical development.
|
- |
Biomica Ltd. (www.biomicamed.com) – developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI;
|
- |
Lavie Bio (www.lavie-bio.com) – developing and commercially advancing, microbiome based ag-biologicals powered by MicroBoost AI;
|
- |
AgPlenus Ltd. (www.agplenus.com) – developing next generation ag-chemicals for effective and sustainable crop protection powered by ChemPass AI;
|
- |
Casterra Ag (www.casterra.co) – developing and marketing superior castor seed varieties producing high yield and high-grade oil content, on an industrial scale for the biofuel and other industries powered by GeneRator AI.
|
June 30,
|
December 31,
|
|||||||
2024
|
2023
|
|||||||
Unaudited
|
Audited
|
|||||||
CURRENT ASSETS:
|
||||||||
Cash and cash equivalents
|
$
|
9,484
|
$
|
20,772
|
||||
Short-term bank deposits
|
11,424
|
10,291
|
||||||
Trade receivables
|
376
|
357
|
||||||
Other receivables and prepaid expenses
|
3,696
|
2,973
|
||||||
Inventories
|
794
|
76
|
||||||
25,774
|
34,469
|
|||||||
LONG-TERM ASSETS:
|
||||||||
Long-term deposits and other receivables
|
30
|
28
|
||||||
Investment accounted for using the equity method
|
100
|
-
|
||||||
Right-of-use-assets
|
729
|
980
|
||||||
Property, plant and equipment, net
|
1,650
|
2,455
|
||||||
Intangible assets, net
|
12,685
|
13,169
|
||||||
15,194
|
16,632
|
|||||||
$
|
40,968
|
$
|
51,101
|
|||||
CURRENT LIABILITIES:
|
||||||||
Trade payables
|
$
|
957
|
$
|
1,785
|
||||
Employees and payroll accruals
|
2,333
|
2,537
|
||||||
Lease liability
|
558
|
853
|
||||||
Liabilities in respect of government grants
|
681
|
388
|
||||||
Deferred revenues and other advances
|
548
|
362
|
||||||
Other payables
|
816
|
1,019
|
||||||
5,893
|
6,944
|
|||||||
LONG-TERM LIABILITIES:
|
||||||||
Lease liability
|
252
|
285
|
||||||
Liabilities in respect of government grants
|
4,247
|
4,426
|
||||||
Deferred revenues and other advances
|
244
|
393
|
||||||
Convertible SAFE
|
10,392
|
10,368
|
||||||
15,135
|
15,472
|
|||||||
SHAREHOLDERS' EQUITY:
|
||||||||
Ordinary shares of NIS 0.2 par value:
Authorized − 15,000,000 ordinary shares; Issued and outstanding − 5,096,760 shares as of June 30,
2024, and 5,079,313 (*) shares as of December 31, 2023
|
287
|
286
|
||||||
Share premium and other capital reserve
|
269,648
|
269,353
|
||||||
Accumulated deficit
|
(266,868
|
)
|
(257,586
|
)
|
||||
Equity attributable to equity holders of the Company
|
3,067
|
12,053
|
||||||
Non-controlling interests
|
16,873
|
16,632
|
||||||
Total equity
|
19,940
|
28,685
|
||||||
$
|
40,968
|
$
|
51,101
|
Six months ended
June 30,
|
Three months ended
June 30,
|
Year ended
December 31,
|
||||||||||||||||||
2024
|
2023
|
2024
|
2023
|
2023
|
||||||||||||||||
Unaudited
|
Audited
|
|||||||||||||||||||
Revenues
|
$
|
5,104
|
$
|
1,295
|
$
|
914
|
$
|
654
|
$
|
5,640
|
||||||||||
Cost of revenues
|
847
|
783
|
537
|
461
|
1,692
|
|||||||||||||||
Gross profit
|
4,257
|
512
|
377
|
193
|
3,948
|
|||||||||||||||
Operating expenses:
|
||||||||||||||||||||
Research and development, net
|
8,817
|
10,169
|
4,016
|
5,369
|
20,777
|
|||||||||||||||
Sales and marketing
|
1,920
|
1,728
|
928
|
928
|
3,611
|
|||||||||||||||
General and administrative
|
3,184
|
3,312
|
1,530
|
1,797
|
6,068
|
|||||||||||||||
Other expenses
|
524
|
-
|
5
|
-
|
-
|
|||||||||||||||
Total operating expenses, net
|
14,445
|
15,209
|
6,479
|
8,094
|
30,456
|
|||||||||||||||
Operating loss
|
(10,188
|
)
|
(14,697
|
)
|
(6,102
|
)
|
(7,901
|
)
|
(26,508
|
)
|
||||||||||
Financing income
|
667
|
699
|
260
|
391
|
1,486
|
|||||||||||||||
Financing expenses
|
(288
|
)
|
(785
|
)
|
(122
|
)
|
(247
|
)
|
(965
|
)
|
||||||||||
Financing income (expenses), net
|
379
|
(86
|
)
|
138
|
144
|
521
|
||||||||||||||
Share of loss from equity accounted investment
|
(20
|
)
|
-
|
(20
|
)
|
-
|
-
|
|||||||||||||
Loss before taxes on income
|
(9,829
|
)
|
(14,783
|
)
|
(5,984
|
)
|
(7,757
|
)
|
(25,987
|
)
|
||||||||||
Taxes on income (tax benefit)
|
1
|
(24
|
)
|
1
|
21
|
(33
|
)
|
|||||||||||||
Loss
|
$
|
(9,830
|
)
|
$
|
(14,759
|
)
|
$
|
(5,985
|
)
|
$
|
(7,778
|
)
|
$
|
(25,954
|
)
|
|||||
Attributable to:
|
||||||||||||||||||||
Equity holders of the Company
|
$
|
(9,282
|
)
|
$
|
(13,294
|
)
|
$
|
(5,419
|
)
|
$
|
(7,023
|
)
|
$
|
(23,879
|
)
|
|||||
Non-controlling interests
|
(548
|
)
|
(1,465
|
)
|
(566
|
)
|
(755
|
)
|
(2,075
|
)
|
||||||||||
$
|
(9,830
|
)
|
$
|
(14,759
|
)
|
$
|
(5,985
|
)
|
$
|
(7,778
|
)
|
$
|
(25,954
|
)
|
||||||
Basic and diluted loss per share, attributable to equity holders of the Company (*)
|
$
|
(1.82
|
)
|
$
|
(3.18
|
)
|
$
|
(1.06
|
)
|
$
|
(1.68
|
)
|
$
|
(5.20
|
)
|
|||||
Weighted average number of shares used in computing basic and diluted loss per share (*)
|
5,087,029
|
4,177,554
|
5,090,993
|
4,185,242
|
4,589,386
|
Six months ended
June 30,
|
Three months ended
June 30,
|
Year ended December 31,
|
||||||||||||||||||
2024
|
2023
|
2024
|
2023
|
2023
|
||||||||||||||||
Unaudited
|
Audited
|
|||||||||||||||||||
Cash flows from operating activities
|
||||||||||||||||||||
Loss
|
$
|
(9,830
|
)
|
$
|
(14,759
|
)
|
$
|
(5,985
|
)
|
$
|
(7,778
|
)
|
$
|
(25,954
|
)
|
|||||
Adjustments to reconcile loss to net cash used in operating activities:
|
||||||||||||||||||||
Adjustments to the profit or loss items:
|
||||||||||||||||||||
Depreciation
|
800
|
807
|
374
|
406
|
1,641
|
|||||||||||||||
Amortization of intangible assets
|
484
|
481
|
239
|
241
|
971
|
|||||||||||||||
Share-based compensation
|
999
|
1,219
|
460
|
801
|
1,877
|
|||||||||||||||
Revaluation of convertible SAFE
|
24
|
220
|
49
|
26
|
254
|
|||||||||||||||
Net financing expenses (income)
|
(222
|
)
|
6
|
(28
|
)
|
60
|
(666
|
)
|
||||||||||||
Loss (gain) from sale of property, plant and equipment
|
524
|
(26
|
)
|
5
|
-
|
(26
|
)
|
|||||||||||||
Share of loss from equity accounted investment
|
20
|
-
|
20
|
-
|
-
|
|||||||||||||||
Taxes on income (tax benefit)
|
1
|
(24
|
)
|
1
|
21
|
(33
|
)
|
|||||||||||||
2,630
|
2,683
|
1,120
|
1,555
|
4,018
|
||||||||||||||||
Changes in asset and liability items:
|
||||||||||||||||||||
Decrease (increase) in trade receivables
|
(19
|
)
|
170
|
163
|
72
|
(9
|
)
|
|||||||||||||
Decrease (increase) in other receivables
|
(725
|
)
|
84
|
(546
|
)
|
375
|
(1,445
|
)
|
||||||||||||
Decrease (increase) in inventories
|
(718
|
)
|
317
|
(78
|
)
|
342
|
490
|
|||||||||||||
Decrease in deferred taxes
|
-
|
-
|
-
|
-
|
94
|
|||||||||||||||
Increase (decrease) in trade payables
|
(762
|
)
|
26
|
(77
|
)
|
(95
|
)
|
742
|
||||||||||||
Increase (decrease) in employees and payroll accruals
|
(204
|
)
|
172
|
(99
|
)
|
117
|
550
|
|||||||||||||
Increase (decrease) in other payables
|
(214
|
)
|
(162
|
)
|
(153
|
)
|
297
|
(534
|
)
|
|||||||||||
Increase (decrease) in deferred revenues and other advances
|
(84
|
)
|
(73
|
)
|
(13
|
)
|
(81
|
)
|
(288
|
)
|
||||||||||
(2,726
|
)
|
534
|
(803
|
)
|
1,027
|
(400
|
)
|
|||||||||||||
Cash received (paid) during the period for:
|
||||||||||||||||||||
Interest received
|
402
|
283
|
231
|
145
|
905
|
|||||||||||||||
Interest paid
|
(41
|
)
|
(66
|
)
|
(18
|
)
|
(30
|
)
|
(115
|
)
|
||||||||||
Taxes paid
|
-
|
(10
|
)
|
-
|
(10
|
)
|
(31
|
)
|
||||||||||||
Net cash used in operating activities
|
$
|
(9,565
|
)
|
$
|
(11,335
|
)
|
$
|
(5,455
|
)
|
$
|
(5,091
|
)
|
$
|
(21,577
|
)
|
Six months ended
June 30,
|
Three months ended
June 30,
|
Year ended
December 31,
|
||||||||||||||||||
2024
|
2023
|
2024
|
2023
|
2023
|
||||||||||||||||
Unaudited
|
Audited
|
|||||||||||||||||||
Cash flows from investing activities:
|
||||||||||||||||||||
Purchase of property, plant and equipment
|
$ |
(172
|
)
|
(483
|
)
|
(31
|
)
|
(124
|
)
|
$
|
(785
|
)
|
||||||||
Proceeds from sale of marketable securities
|
-
|
6,924
|
-
|
6,287
|
6,924
|
|||||||||||||||
Purchase of marketable securities
|
-
|
(503
|
)
|
-
|
(503
|
)
|
(503
|
)
|
||||||||||||
Proceeds from sale of property, plant and equipment
|
10
|
26
|
-
|
-
|
26
|
|||||||||||||||
Withdrawal from (investment in) bank deposits, net
|
(990
|
)
|
(13,560
|
)
|
3,241
|
(13,560
|
)
|
(10,200
|
)
|
|||||||||||
Net cash provided by (used in) investing activities
|
$
|
(1,152
|
)
|
$
|
(7,596
|
)
|
$
|
3,210
|
$
|
(7,900
|
)
|
$
|
(4,538
|
)
|
||||||
Cash flows from financing activities:
|
||||||||||||||||||||
Issuance of a subsidiary preferred shares to non-controlling interests
|
-
|
9,523
|
-
|
9,523
|
9,523
|
|||||||||||||||
Proceeds from issuance of ordinary shares, net of issuance expenses
|
86
|
336
|
83
|
68
|
8,449
|
|||||||||||||||
Repayment of lease liability
|
(462
|
)
|
(413
|
)
|
(231
|
)
|
(207
|
)
|
(836
|
)
|
||||||||||
Proceeds from government grants
|
-
|
1,089
|
-
|
1,063
|
1,089
|
|||||||||||||||
Repayment of government grants
|
(142
|
)
|
(35
|
)
|
(3
|
)
|
-
|
(73
|
)
|
|||||||||||
Net cash provided by (used in) financing activities
|
(518
|
)
|
10,500
|
(151
|
)
|
10,447
|
18,152
|
|||||||||||||
Exchange rate differences - cash and cash equivalent balances
|
(53
|
)
|
(316
|
)
|
(35
|
)
|
(223
|
)
|
(245
|
)
|
||||||||||
Decrease in cash and cash equivalents
|
(11,288
|
)
|
(8,747
|
)
|
(2,431
|
)
|
(2,767
|
)
|
(8,208
|
)
|
||||||||||
Cash and cash equivalents, beginning of the period
|
20,772
|
28,980
|
11,915
|
23,000
|
28,980
|
|||||||||||||||
Cash and cash equivalents, end of the period
|
$
|
9,484
|
$
|
20,233
|
$
|
9,484
|
$
|
20,233
|
$
|
20,772
|
||||||||||
Significant non-cash activities
|
||||||||||||||||||||
Acquisition of property, plant and equipment
|
$
|
15
|
$
|
90
|
$
|
15
|
$
|
21
|
$
|
81
|
||||||||||
Investment in equity-accounted investee with corresponding deferred revenues
|
$
|
120
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
-
|
||||||||||
Increase of right-of-use asset recognized with corresponding lease liability
|
$
|
184
|
$
|
135
|
$
|
54
|
$
|
64
|
$
|
194
|
1 Year Evogene Chart |
1 Month Evogene Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions